Millennium stays at neutral from Merrill

Millennium Pharmaceuticals, Inc. was maintained at its neutral rating by Merrill Lynch analyst Tom McGahren. The company released abstracts for the American Society of Hematology meeting highlighting Velcade's efficacy in various combination regimens, its use in the front-line and retreatment multiple myeloma settings and in non-Hodgkin's lymphoma. An expanded label for Velcade in mantle cell lymphoma is expected by Dec. 9, according to the analyst. Shares of the Cambridge, Mass.-based pharmaceutical company were down 8 cents, or 0.71%, at $11.17. (Nasdaq: MLNM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.